ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRX Tissue Regenix Group Plc

61.50
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 61.50 23,744 08:00:00
Bid Price Offer Price High Price Low Price Open Price
61.00 62.00 61.50 61.50 61.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 24.48M -2.7M -0.0382 -16.10 43.4M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:21:46 O 450 61.00 GBX

Tissue Regenix (TRX) Latest News

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:21:4861.00450274.50O
15:20:2061.053,0001,831.50O
15:05:3261.40746458.04O
12:09:4561.051,000610.50O
11:23:3661.0010,0006,100.00O

Tissue Regenix (TRX) Top Chat Posts

Top Posts
Posted at 10/4/2024 22:19 by pj84
One of the main drawbacks of investing in early stage biotech companies is the need to keep raising funds but the report indicates the current cash should be sufficient.
Posted at 20/3/2024 15:32 by mickhay3
https://youtu.be/c98fRkiZB_Q?si=MOPjIJcp2geq6EEmYear-end presentation trx Dec 2023
Posted at 23/2/2024 15:01 by bamboo2
p1nk, yes, 71 is key.

Rising price with rising volume is always a good combination.
Posted at 22/2/2024 09:43 by bamboo2
Pattern based target price is 75
Resistance at 70-71
Posted at 05/9/2023 07:47 by cliffpeat
@tnt99
re: "takeover target" - the Chairman's statement on the interims appears to be "setting out the stall" saying:

"We have created a commercially focussed global regenerative medtech company in a high-growth sector focused on soft tissues and bone, with a multi-billion-dollar addressable market opportunity in the United States ('US') alone."

Could you share your workings supporting your suggestion of a potential 2024 profit of $8-10m and what % level of growth (compared to H1) would be required?

The balance sheet shows high inventory, trade debtors and intangibles - and constant reference to EBITDA might be a red flag for some.

Will be interesting to see whether the positive H1 results today move the share price at all.
Posted at 05/9/2023 07:24 by tnt99
With this sort of growth must become a takeover target now we should finally see a re rate to the share price Must be over 1.00 pound by ChristmasAnd the potential for a 8-10 million profit next year and an expected market cap over 100 millionThat's my thoughts It's been a long road though !!
Posted at 04/9/2023 15:03 by tnt99
The path to profitability has been achieved and I hope the figure of between 1 and 3 million profit is made in the results tomorrow Any better should see a jump in the share price
Posted at 31/8/2023 08:41 by p1nkfish
Collateralized loan note.

It's a loan that pays interest and/or issues share in the company in exchange for the lender taking part. There can be a redemption date where the borrowing is paid back via issued shares, or some per year.

The exact terms vary depending on the borrower and they can vary widely. The lenders can be offered a variety of ways to achieve a benefit. Sometimes the major shareholders influence how it is packaged.

It is not the same as issuing discounted shares into the market. I took part in the CRX offering and TRX might make a decent candidate for raising that way especially given the share register.

From memory Mills (Harwood), Sneller (Inthallo) and Griffiths were all on the CRX register and took part. Guess who is on the TRX register.
Posted at 23/3/2023 15:53 by timmy40
Sorry I cannot see this back at 0.50, the results were positive with +20% revenue across all divisions + cash in the bank to get to break even. The company is growing revenue in existing markets, particularly the US, as elective surgeries return/increase in frequency after Covid. They are expanding to new geographies/markets too, most probably China/Asia in the near future.The consolidation is required given the share price/no of shares in issue. A higher share price will mean the company is more marketable to institutions. It is v common in the US, which is the largest market by far for TRX and their board are Americans ? There is no dilution overall. This is all v good news. TRX's management are doing an excellent job but just imo.
Posted at 11/8/2022 11:11 by livewireplus
:-)) unfortunately no refunds ... but had some good times ... have ended-up married - but as wife earns more than me then can't complain .... pass the Tissue from the left-hand side. An interesting week so far for the TRX share price ....
Tissue Regenix share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock